PT  - JOURNAL ARTICLE
AU  - Parry, Nicola
ED  - Smith, Matthew R.
TI  - ERA 223 to Study Radium-223 and Abiraterone in Combination in mCRPC
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 17--18
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/17.short
4100  - http://mdc.sagepub.com/content/14/36/17.full
AB  - Skeletal metastases are common in prostate cancer, occurring in approximately 90% of men with advanced disease. Bone metastases result in decreased quality of life by causing problems such as bone pain, morbidity, pathologic fracture, and spinal cord compression. This article discusses the Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Subjects With Bone Predominant Metastatic Castration-Resistant Prostate Cancer trial [ERA 223; NCT02043678].